New contraceptive methods: Update 2003

Current Opinion in Pediatrics

Volumn 15, Issue 4, 2003, Pages 362-369

  Pettinato, Andrea ^a   Emans, S Jean ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORELGESTROMIN; NORGESTIMATE; UNCLASSIFIED DRUG;

ABSTINENCE; ADOLESCENT; ADOLESCENT PREGNANCY; ADULT; BIRTH CONTROL; CONDOM; CONTRACEPTION; COUNSELING; DEVICE; EDUCATION; FAMILY PLANNING; FEMALE; FIRST PASS EFFECT; HORMONAL CONTRACEPTION; HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; TRANSDERMAL PATCH; VAGINA CONTRACEPTION; VAGINA RING;

EID: 0043240309     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200308000-00002     Document Type: Review

References (55)

1. Rosenberg MJ, Waugh MS, Long S: Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med 1995, 40:355-360.
2. Ventura SJ, Mathews TJ, Hamilton BE: Teenage births in the United States: state trends, 1991-2000, an update. Natl Vital Stat Rep 2002, 50:1-4.
3. Grunbaum JA, Kann L, Kinchen SA, et al.: Youth risk behavior surveillance-United States, 2001. MMWR Morb Mortal Wkly Rep 2002, 51:1-62.
4. The Alan Guttmacher Institute: Facts in Brief: Teen Sex and Pregnancy. 1999. Available at: http://www.agi.usa.org/pubs/fb_teen_sex.html
5. World Health Organization: WHO website for medical eligibility criteria 2001. Available at: www.who.int/reproductive-health/publications/ RHR_00_2_medical_eligibility_criteria_second_edition/ medical_eligibility_crtieria_table_of_contents.en.htm This website provides practitioners for the latest evidence-based World Health Organization Guidelines for the provision of contraception. Each medical condition is followed by four categories for each class of contraceptive. Tables 1 and 2 in this article are drawn from this publication. The print version is reference [6].
6. World Health Organization: Improving Access to Quality Care in Family Planning. Medical Eligibility Criteria for Contraceptive Use. Geneva, WHO, 2000.
7. Abrams LS, Skee D, Natarajan J, Wong FA. Pharmacokinetic overview of Ortho Evra/Evra. Fertil Steril 2002, 77(2 Suppl 2):S3-12. A comprehensive overview of the pharmacokinetics of the transdermal patch that includes information on the effect of duration, various application sites, various conditions such as humidity, and drug interactions. Of note, this supplement has additional articles on all aspects of the efficacy, safety, and tolerability of the patch.
8. Abrams LS, Skee DM, Natarajan J, et al: Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Br J Clin Pharmacol 2002, 53:141-146.
9. Zacur HA, Hedon B, Mansour D, et al: Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril 2002, 77(2 Suppl 2):S32-5.
10. Zieman M, Guillebaud J, Weisberg E, et al: Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002, 77(2 Suppl 2):S13-8.
11. Sibai BM, Odlind V, Meador ML, et al: A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002, 77(2 Suppl 2):S19-26. This article is from the same supplement as [10] and addresses the occurrence of adverse side effects of the patch compared with a standard oral contraceptive.
12. Archer DF, Bigrigg A, Smallwood GH, et al: Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 2002, 77(2 Suppl 2):S27-31.
13. Anonymous: FDA approves NuvaRing contraceptive implant. J Gend Specif Med 2002, 5:6.
14. Mulders TM, Dieben TO, Bennink HJ: Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002, 17:2594-2599.
15. Timmer CJ, Mulders TM: Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000, 39:233-242.
16. Davies GC, Feng LX, Newton JR, et al: Ovarian activity and bleeding patterns during extended continuous use of a combined contraceptive vaginal ring. Contraception 1992, 48:269-278.
17. Bjarnadottir RI, Tuppurainen M, Killick SR: Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002, 186:389-395. This study compared the ring to a standard oral contraceptive and found a significantly higher incidence of normal intended bleeding patterns, enhancing its acceptability as a new contraceptive method.
18. Roumen FJ, Apter D, Mulders TM, et al: Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001, 16:469-475.
19. Dieben TO, Roumen FJ, Apter D: Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002, 100:585-593. This study provides evidence that the contraceptive vaginal ring provides effective contraception and good cycle control and is well tolerated and accepted as a new birth control method.
20. Mulders TM, Dieben TO: Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001, 75:865-870.
21. Davies GC, Feng LX, Newton JR, et al: The effects of a combined contraceptive vaginal ring releasing ethinyloestradiol and 3-ketodesogestrel on vaginal flora. Contraception 1992, 45:511-518.
22. Lahteenmaki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contraception. Steroids 2000, 65:693-697.
23. Luukkainen T: Contraception after thirty-five. Acta Obstet Gynecol Scand 1992, 71:169-174.
24. Nilsson CG, Johansson ED, Jackanicz TM, et al: Biodegradable polylactate as a steroid-releasing polymer: intrauterine administration of d-norgestrel. Am J Obstet Gynecol 1975, 122:90-95.
25. Jonsson B, Landgren BM, Eneroth P: Effects of various IUDs on the composition of cervical mucus. Contraception 1991, 43:447-458.
26. Silverberg SG, Haukkamaa M, Arko H, et al: Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 1986, 5:235-241.
27. Chi IC: The TCu-380A (AG), MLCu375, and Nova-T IUDs and the IUD daily releasing 20 micrograms levonorgestrel-four pillars of IUD contraception for the nineties and beyond? Contraception 1993, 47:325-347.
28. Andersson K, Odlind V, Rybo G: Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994, 49:56-72.
29. Luukkainen T, Allonen H, Haukkamaa M, et al: Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception 1987, 36:169-179.
30. Diaz J, Faundes A, Diaz M, et al: Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil. Contraception. 1993, 47:169-175.
31. Diaz J, Bahamondes L, Monteiro I, et al: Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas. Brazil. Contraception. 2000, 62:59-61.
32. Faundes A, Alvarez F, Diaz J: A Latin American experience with levonorgestrel IUD. Ann Med 1993, 25:149-153.
33. Dubuisson JB, Mugnier E: Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years. Contraception 2002, 66:121-128. This is a recent study of the LNG-IUS, which demonstrates high acceptability with a continuation rate of 88.7% after 1 year among woman 35 to 45 years old. The article reinforces the efficacy and safety of the device.
34. Backman T, Huhtala S, Luoto R, et al: Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002, 99:608-613.
35. Monteiro I, Bahamondes L, Diaz J, et al: Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study (1). Contraception 2002, 65:325-328.
36. Hidalgo M, Bahamondes L, Perrotti M, et al: Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002, 65:129-132. This recent study helps support previous findings that the LNG-IUS is a highly effective birth control method that reduces menstrual bleeding and has a low pelvic infection risk.
37. Ronnerdag M, Odlind V: Health effects of long-term use of the intrauterine levonorgestrel-releasing system: a follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999, 78:716-721.
38. Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000, 62:29-38.
39. Anonymous: Yasmin-an oral contraceptive with a new progestin. Med Lett Drugs Ther 2002, 44:55-57. [erratum appears in Med Lett Drugs Ther 2002, 44:70]
40. Parsey KS, Pong A: An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000, 61:105-111. This study reports the initial findings that Yasmin is an effective, well-tolerated, and safe new oral contraceptive, based on a comparison with published statistics of other, similar oral contraceptives.
41. Oelkers W, Foidart JM, Dombrovicz N, et al: Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabohsm. J Clin Endocrinol Metab 1995, 80:1816-1821.
42. Oelkers W, Helmerhorst FM, Wuttke We, et al: Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers [comment]. Gynecol Endocrinol 2000, 14:204-213.
43. Huber J, Foidart JM, Wuttke W, et al: The efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000, 5:25-34. [erratum appears in Eur J Contracept Reprod Health Care 2001, 6:63]
44. van Vloten WA, van Haselen CW, van Zuuren EJ, et al: The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002, 69(4 Suppl):2-15.
45. Sheldon T: Dutch GPs warned against new contraceptive pill. BMJ 2002, 324:869. This statement reminds us that further postmarketing studies are needed to ensure that the risks associated with Yasmin are comparable to the risks of other oral contraceptives.
46. Kaunitz AM, Garceau RJ, Cromie MA: Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group. Contraception 1999, 60:179-187.
47. Anonymous: A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection: I. Contraceptive efficacy and side effects. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 1988, 37:1-20.
48. Newton JR, D'Arcangues C, Hall PE: A review of "once-a-month" combined injectable contraceptives. J Obstet Gynaecol 1994, 4(Suppl 1):S1-34.
49. Sang GW, Shao OX, Ge RS, et al: A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and side effects. Contraception 1995, 51:167-183.
50. Garceau RJ, Wajszczuk CJ, Kaunitz AM, et al: Bleeding patterns of women using Lunelle monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives. Contraception 2000, 62:289-295.
51. Jain JK, Ota F, Mishell DR: Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive. Contraception 2000, 61:195-198.
52. Rahimy MH, Ryan KK: Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women. Contraception 1999, 60:189-200.
53. Cromie MA, Maile MH, Wajszczuk CP: Comparative effects of Luneile monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic) on lipid profiles. Investigators from the Lunelle Study Group. Contraception 2000, 61:51-59.
54. Rahimy MH, Cromie MA, Hopkins NK, et al: Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics. Contraception 1999, 60:201-208.
55. Shulman LP, Oleen-Burkey M, Willke RJ: Patient acceptability and satisfaction with Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension). Contraception 1999, 60:215-222.